- Home
- PLCE vs ADVM Comparison
PLCE vs ADVM Comparison
Compare PLCE & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLCE
- ADVM
- Stock Information
- Founded
- PLCE 1969
- ADVM 2006
- Country
- PLCE United States
- ADVM United States
- Employees
- PLCE N/A
- ADVM N/A
- Industry
- PLCE Clothing/Shoe/Accessory Stores
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PLCE Consumer Discretionary
- ADVM Health Care
- Exchange
- PLCE Nasdaq
- ADVM Nasdaq
- Market Cap
- PLCE 106.6M
- ADVM 98.0M
- IPO Year
- PLCE 1997
- ADVM 2014
- Fundamental
- Price
- PLCE $8.74
- ADVM $4.45
- Analyst Decision
- PLCE Hold
- ADVM Strong Buy
- Analyst Count
- PLCE 3
- ADVM 6
- Target Price
- PLCE $8.33
- ADVM $27.83
- AVG Volume (30 Days)
- PLCE 313.7K
- ADVM 136.1K
- Earning Date
- PLCE 04-11-2025
- ADVM 05-08-2025
- Dividend Yield
- PLCE N/A
- ADVM N/A
- EPS Growth
- PLCE N/A
- ADVM N/A
- EPS
- PLCE N/A
- ADVM N/A
- Revenue
- PLCE $1,432,740,000.00
- ADVM $1,000,000.00
- Revenue This Year
- PLCE N/A
- ADVM N/A
- Revenue Next Year
- PLCE N/A
- ADVM $1,162.55
- P/E Ratio
- PLCE N/A
- ADVM N/A
- Revenue Growth
- PLCE N/A
- ADVM N/A
- 52 Week Low
- PLCE $4.77
- ADVM $3.52
- 52 Week High
- PLCE $19.74
- ADVM $14.21
- Technical
- Relative Strength Index (RSI)
- PLCE 51.10
- ADVM 45.50
- Support Level
- PLCE $8.47
- ADVM $4.76
- Resistance Level
- PLCE $9.47
- ADVM $5.23
- Average True Range (ATR)
- PLCE 0.67
- ADVM 0.48
- MACD
- PLCE 0.16
- ADVM -0.05
- Stochastic Oscillator
- PLCE 72.03
- ADVM 20.52
About PLCE Children's Place Inc. (The)
Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It design, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.